Want to see CH:EVE full AI Analyst Report?
EVE Stock Chart & Stats
CHF2.32
-CHF0.13(-5.80%)
At close: 4:00 PM EDT
CHF2.32
-CHF0.13(-5.80%)
Day’s Range― - ―
52-Week RangeCHF0.75 - CHF2.74
Previous CloseN/A
Volume1.72K
Average Volume (3M)25.32K
Market Cap
CHF15.00M
Enterprise ValueCHF13.09
Total Cash (Recent Filing)CHF5.61M
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding7,230,626
10 Day Avg. Volume27,387
30 Day Avg. Volume25,324
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.5
Revenue Forecast (FY)CHF60.90M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe absence of reported debt reduces interest obligations and refinancing exposure, giving Evolva greater financial flexibility than a similarly loss-making, highly leveraged company. This provides some capacity to preserve assets and pursue strategic options during the next several quarters.
Reduced Cash BurnA meaningful reduction in cash burn improves the company’s near-term financial runway and may indicate tighter cost control or a smaller operating footprint. Although operations remain cash consumptive, lower outflows can slow balance-sheet erosion over the next two to six months.
Biotechnology Platform And IPEvolva’s historical biotechnology and fermentation capabilities, together with ingredient products and intellectual property, provide a differentiated basis for specialty-ingredient development. If effectively commercialized, this platform could support higher-value applications across nutrition, health, and wellness.
Bears Say
No Current Revenue BaseRevenue of zero for two consecutive reported years signals a severe loss of operating scale and leaves no demonstrated sales engine supporting the business. Without restored commercial activity, the company has limited evidence of recurring demand or a durable path to self-sustaining growth.
Persistent Cash ConsumptionContinuous negative operating and free cash flow shows that the business has not funded itself through operations across the reported period. Even with reduced recent burn, ongoing cash consumption can require financing or asset reductions and may constrain investment in future growth.
Shrinking Capital Base And Unstable ProfitabilityMaterial declines in equity and assets indicate that cumulative losses and cash burn have weakened the capital base. The reversal from 2024 profit to 2025 loss further demonstrates unstable earnings power, making sustained shareholder value creation difficult to establish.
Evolva Holding News
EVE FAQ
What was Evolva Holding’s price range in the past 12 months?
Evolva Holding lowest stock price was CHF0.75 and its highest was CHF2.74 in the past 12 months.
What is Evolva Holding’s market cap?
Evolva Holding’s market cap is CHF15.00M.
When is Evolva Holding’s upcoming earnings report date?
Evolva Holding’s upcoming earnings report date is Feb 19, 2027 which is in 140 days.
How were Evolva Holding’s earnings last quarter?
Evolva Holding released its earnings results on Aug 26, 2026. The company reported -CHF0.088 earnings per share for the quarter.
Is Evolva Holding overvalued?
According to Wall Street analysts Evolva Holding’s price is currently Overvalued.
Does Evolva Holding pay dividends?
Evolva Holding does not currently pay dividends.
What is Evolva Holding’s EPS estimate?
Evolva Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evolva Holding have?
Evolva Holding has 7,230,626 shares outstanding.
What happened to Evolva Holding’s price movement after its last earnings report?
Evolva Holding reported an EPS of -CHF0.088 in its last earnings report. Following the earnings report the stock price went up 3.017%.
Which hedge fund is a major shareholder of Evolva Holding?
Currently, no hedge funds are holding shares in CH:EVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evolva Holding
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith. Its corporate headquarters are located in Reinach, Switzerland.
Technical Analysis
Molecular Partners AG
―
Lonza Group Ltd
―
Bachem Holding AG
―
Kuros Biosciences
―
Xlife Sciences Ltd.
―